Home › Compare › ITXXF vs ABBV
ITXXF yields 166.65% · ABBV yields 3.06%● Live data
📍 ITXXF pulled ahead of the other in Year 1
Combined, ITXXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ITXXF + ABBV for your $10,000?
Itaconix plc, together with its subsidiaries, designs, develops, manufactures, and sells bio-based polymers for personal care, home care, and industrial sectors in North America and Europe. The company's home care and industrial products include Itaconix TSI 322, Itaconix DSP 2K, Itaconix TSI 122, and Itaconix VELASOFT water soluble polymers; and Itaconix ZINADOR 22L and 35L, which are water soluble odor neutralizers. Its personal care products comprise Itaconix VELAFRESH ZP20 and ZP30 that are water soluble fixating complexes; and Nouryon Amaze SP, a hair styling ingredient. The company was formerly known as Revolymer plc and changed its name to Itaconix plc in February 2017. Itaconix plc was incorporated in 2012 and is headquartered in Stratham, New Hampshire.
Full ITXXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.